Editors' Note: In reference to "Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders," Blum et al. describe 2 cases of patients with neuromyelitis optica spectrum disorder detected by cell-based assay but negative on ELISA. Authors Sato et al. answer their questions about aquaporin-4 antibody testing. Verghese presents a case of myoclonus in a patient with type III Gaucher disease.

—Megan Alcauskas, MD, and Robert C. Griggs, MD

AQUAPORIN-4 ANTIBODY-POSITIVE CASES BEYOND CURRENT DIAGNOSTIC CRITERIA FOR NMO SPECTRUM DISORDERS

Stefan Blum, Bob Wilson, Kerri Prain, Richard Wong, David Gills, Brisbane, Australia: Sato et al.¹

described 13 cases of neuromyelitis optica spectrum disorder (NMO-SD) and 3 of those cases had brainstem involvement in which antibodies (Ab) to the M1 isoform of aquaporin-4 (AQP4) were detected by a cell-based assay (CBA) but not by an ELISA.

We saw 2 patients with NMO-SD who had lesions in the posterior pons adjacent to the floor of the fourth ventricle. Both had a similar clinical presentation of nystagmus and intranuclear ophthalmoplegia. One subject had further relapses with intractable nausea, hiccups, and gait ataxia and developed bilateral thalamic lesions. Neither had optic neuritis or spinal cord disease and both responded well to aggressive immunosuppressive therapy.

Similar to Sato et al., sera from these subjects were positive for AQP4-Ab on a commercial CBA (Euroimmun, Luebeck, Germany) but negative by indirect immunofluorescence on unfixed rodent brain tissue, indicating a lack of binding to the native protein. It is possible that these antibodies detected an epitope exposed on the cells transfected with M1 but not on native AQP4 or in the ELISA assay. Different structural arrangement of AQP4 in cell membranes could lead to a different epitope.^{2,3}

Author Response: Douglas K. Sato, Toshiyuki Takahashi, Kazuo Fujihara, Sendai, Japan: We thank Blum et al. for their comments. Their 2 cases show that AQP4-Ab seropositivity is critical for the diagnosis of the NMO-SD without typical attacks of optic neuritis, longitudinally extensive myelitis, or both.

Blum et al. also questioned the AQP4 epitopes and differences on the assay sensitivities using nonhuman AQP4, human AQP4 isoforms, or fixed material. There are differences on the rodent and the human AQP4 proteins, so some patients' AQP4-Ab may not recognize rodent epitopes, providing negative results.⁴ In addition, the human AQP4-M23 used in our CBA¹ was able to form orthogonal array of particles (OAP) in the cell membrane⁵ that are not observed using either AQP4-M1 or linearized AQP4 (ELISA). These OAPs increased the assay sensitivity, as antibodies are more likely to recognize this large 3D structure. We have not seen a sample that has been positive on AQP4-M1 and not on AQP4-M23, and this has been confirmed.^{6,7} Finally, fixation prior to exposure (commercial CBA) to human sera may reduce assay sensitivity.⁷ In our study, the cells were only fixed after the secondary antibody.

© 2014 American Academy of Neurology

1. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. *Neurology* 2013;80:2210–2216.
2. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. *Nat Rev Neurol* 2010;6:383–392.
3. Furman CS, Gorelick-Feldman DA, Davidson KG, et al. Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. *Proc Natl Acad Sci USA* 2003;100:13609–13614.
4. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. *Neurology* 2012;78:665–671.
5. Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. *J Biol Chem* 2011;286:16516–16524.
6. Mader S, Lutterotti A, Di Pauli F, et al. Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. *PLoS One* 2010;5:e10455.
7. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. *Neurology* 2013;80:2194–2200.

THALAMIC GLUTAMATE/GLUTAMINE IN RESTLESS LEGS SYNDROME: INCREASED AND RELATED TO DISTURBED SLEEP

Iain Jordan, Declan Murray, Dublin: Allen et al.¹ reported elevated thalamic glutamate levels in restless

Neurology®

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders

Stefan Blum, Douglas K. Sato, Bob Wilson, et al.

Neurology 2014;82;372

DOI 10.1212/WNL.0000000000000005

This information is current as of January 27, 2014

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/82/4/372.1.full>

References

This article cites 7 articles, 5 of which you can access for free at:
<http://n.neurology.org/content/82/4/372.1.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.